T-helper 17 (Th17) cells have important functions in adaptor immunity and have also been implicated in inflammatory disorders. The bromodomain and extraterminal domain (BET) family proteins regulate gene transcription during lineage-specific differentiation of naïve CD4
T-helper 17 (Th17) cells have important functions in adaptor immunity and have also been implicated in inflammatory disorders. The bromodomain and extraterminal domain (BET) family proteins regulate gene transcription during lineage-specific differentiation of naïve CD4 + T cells to produce mature T-helper cells. Inhibition of acetyl-lysine binding of the BET proteins by pan-BET bromodomain (BrD) inhibitors, such as JQ1, broadly affects differentiation of Th17, Th1, and Th2 cells that have distinct immune functions, thus limiting their therapeutic potential. Whether these BET proteins represent viable new epigenetic drug targets for inflammatory disorders has remained an unanswered question. In this study, we report that selective inhibition of the first bromodomain of BET proteins with our newly designed small molecule MS402 inhibits primarily Th17 cell differentiation with a little or almost no effect on Th1 or Th2 and Treg cells. MS402 preferentially renders Brd4 binding to Th17 signature gene loci over those of housekeeping genes and reduces Brd4 recruitment of p-TEFb to phosphorylate and activate RNA polymerase II for transcription elongation. We further show that MS402 prevents and ameliorates T-cell transfer-induced colitis in mice by blocking Th17 cell overdevelopment. Thus, selective pharmacological modulation of individual bromodomains likely represents a strategy for treatment of inflammatory bowel diseases. + T cells are important immune cells in biology and have been implicated in the pathology of autoimmune diseases and cancer (1) (2) (3) (4) (5) . They develop in thymus to different T-helper (Th) cells to guide immune effector functions (6) . The known Th effector subsets including Th1, Th2, Th17, and Treg produce signature genes and perform different immune functions (7, 8) . Particularly, Th17 cells produce IL-17a and IL-17f and protect mucosa from bacterial and fungal infection (9, 10) . Th17 cell development is linked to inflammatory disorders including multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease (11) (12) (13) .
Lineage-specific differentiation of naïve CD4 + T cells to Th17 cells is tightly controlled by gene transcription in chromatin (14-16)-a complex process that involves collective activities of key transcription factors Stat3, Batf, and Irf4, as well as Th17-specific orphan nuclear receptor RORγT (17) (18) (19) (20) . These transcription factors work with chromatin modifying enzymes and effector proteins to ensure proper timing, duration, and amplitude for ordered gene transcription in Th17 cell differentiation (15, 21) . Of these are a family of bromodomain (BrD) and extraterminal domain (BET) proteins consisting of Brd2, Brd3, Brd4, and testis-specific Brdt (22, 23) . BET proteins play a multifaceted role in gene transcription through their tandem bromodomains binding to lysine-acetylated histones and transcription factors during chromatin opening, transcription factor recruitment to target gene promoter and enhancer sites, and activation of paused RNA polymerase II (PolII) transcriptional machinery for productive gene activation (24, 25) . Consistent with their role in T-helper-cell differentiation (26) , inhibition of acetyl-lysine binding of the BET proteins by pan-BET BrD inhibitors, such as JQ1, affects differentiation of not only Th17 but also of Th1 and Th2 cells (27, 28) . Because of such broad activities, unfortunately, pan-BET BrD inhibitors are thought to have limited therapeutic potential. Whether these BET proteins represent viable new epigenetic drug targets for inflammatory disorders has remained an unanswered question to this day.
Growing evidence shows that the two BrDs of BET proteins have distinct functions in gene transcription in that the second BrD (BD2) of Brd4 is dedicated to interaction with lysine-acetylated transcription factors and p-TEFb, whereas the first BrD (BD1) functions to anchor the activated Brd4/transcription protein
Significance
The bromodomain and extraterminal domain (BET) proteins regulate transcription of subset-specifying genes during lineage-specific T-helper-cell differentiation in adaptor immunity and are also implicated in inflammatory disorders. The available pan-BET bromodomain inhibitors such as JQ1 indiscriminately block the tandem bromodomains (BD1 and BD2) of the BET proteins, broadly render differentiation of different Th subsets, and have limited therapeutic potential. Here we report a small molecule, MS402, that can selectively inhibit BD1 over BD2 of the BET proteins and block Th17 maturation from mouse naive CD4 + T cells, with limited or no effects on Th1, Th2, or Treg cells. MS402 effectively prevents and ameliorates T-cell transfer-induced colitis in mice by disrupting Th17 cell development, thus representing a therapeutic approach for inflammatory bowel diseases.
complex to target genes in chromatin through binding to lysineacetylated histone H4 (26, 29) . We sought to investigate how selective BET BrD inhibition modulates gene transcription in lineage-specific differentiation of different Th subsets. In this study, we have developed a BD1-selective BET BrD inhibitor, MS402, and showed that it can selectively render differentiation of Th17 cells over other Th cells from murine primary naïve CD4 + T cells. We further demonstrated the therapeutic potential of MS402 in preventing and ameliorating adaptive T-cell transfer-induced colitis in mice through the disruption of Brd4 functions in gene transcription and Th17 cell development.
Results and Discussion
Given that the BD1 of the BET proteins is dedicated for binding to lysine-acetylated histone H4 for gene transcriptional activation (30) , we reasoned that a small molecule that selectively targets the BD1 could effectively block BET functions in gene activation in chromatin. Using structure-guided design, we developed a cyclopentanone-based BrD inhibitor, MS402 (see its synthesis in Scheme S1), that displays nanomolar inhibitory activity against the BD1 (K i of 77 nM) with a ninefold selectivity over BD2 of BRD4 (Fig. 1A) . This selectivity is consistently seen with the BrDs of BRD2 or BRD3, albeit to a lesser extent (Fig. S1A) . The BrD of CREB-binding protein (CBP) binds MS402 with K i of 775 nM, 10-fold weaker than BRD4-BD1, and other representative BrDs from different subgroups of the BrD family including PCAF, SMARCA4, BPTF, and BAZ2B show very weak binding to MS402 with 50-fold or more less affinity than BRD4-BD1 ( Fig. S1 A and B) . MS402 is 200-300 times more potent than K5ac/K8ac-di-acetylated H4 peptide in binding to BRD4 BrDs (Fig. 1A) . Our 1.5-Å-resolution crystal structure of the BRD4 BD1 revealed that MS402 is bound across the ZA channel, establishing interactions with Val87, Leu92, and Leu94 on one side and Trp81, Pro82, Phe83, and Ile146 on the other (Fig. 1B and Table S1 ). The carbonyl oxygen of its cyclopentanone moiety forms two key hydrogen bonds, one with the side-chain amide of the conserved Asn140 and the other mediated by a bound water molecule to the phenoxyl group of Tyr97. In addition, this moiety makes van der Waals contacts with a gatekeeper residue Ile146. The amino group connecting cyclopentanone and chlorobenzene forms another hydrogen bond to the backbone carbonyl oxygen of Pro82 of the WPF shelf. Further, the amide nitrogen linking the two aromatic rings of MS402 forms a water-mediated hydrogen bond to the side-chain carbonyl oxygen of Gln85. The latter is unique in the BD1, corresponding to a Lys in the BD2 that is not engaged in hydrogen bond binding to MS402 as does Gln85 in BD1; point mutation of Gln85 to a Lys or Ala nearly abolished the preferred MS402 binding by BD1 over BD2 (Fig. S1 B-D) . Further, change of Ile146 in BD1 to smaller Val439 in BD2 likely weakens van der Waals contacts between the protein and cyclopentanone, thus explaining MS402 selectivity for the BD1 over BD2 of BRD4.
To study the role of BET proteins in Th cell differentiation we isolated murine primary naïve CD4 + T cells from mouse spleen and lymph nodes and treated them with IL-12, IL-4 plus α-IL-12, TGF-β plus IL-6, or TGF-β plus IL-2, respectively, to promote Th1, Th2, Th17, or Treg linage-specific differentiation over 3.5 d with or without MS402 added daily to cell culture ( Fig. 2A) . Strikingly, as shown by flow cytometry analysis, MS402, in a dose-dependent manner, inhibited IL-17 release from 18.6 to 8.0% in the Th17 polarizing condition and to a lesser extent IFN-γ production from 49.7 to 38.6% in the Th1 condition; it had little, if any, effect on IL-4 and Foxp3 expression during Th2 and Treg cell differentiation, respectively (Fig.  2B ). MS402 did not affect T-cell proliferation as assessed in a carboxy-fluorescein succinimidyl ester dilution assay (Fig. S2A) .
Notably, MS417, a potent pan-BET BrD inhibitor (K i <10 nM) (26) , and JQ1 (31) and I-BET762 (32) that share the diazepine scaffold, block broadly differentiation of murine primary naïve CD4
+ T cells to Th17, Th1, Th2, and, to a lesser extent, Treg cells under the conditions similar to those used for MS402 ( Fig. 2B and Fig. S2 B-D). Our data agree with a report of suppression of Th17-mediated pathology by JQ1 (28) . Further, a potent, selective CBP BrD inhibitor, CBP30 (K d = 26 nM), was reported to suppress Th17 cell differentiation (33) . Using the same condition, however, we found that CBP30 inhibits Th17 and also Th2 cell differentiation and has limited effects on Th1 or Treg cells (Fig.  S2E ). These results argue that MS402's modest activity on CBP BrD (K i of 775 nM, 10-fold weaker than Brd4-BD1) likely does not contribute to its selective activity on Th17 cell differentiation, especially when used at submicromolar concentrations.
The selective activity of MS402 on inhibition of Th17 cell differentiation over Th1, Th2, or Treg cells is further supported by our observations that in a dose-dependent manner MS402 effectively inhibits transcriptional activation of rorc and il17a in Th17 cells, and to a lesser extent tbx21 and ifng in Th1 cells, and it has only small effects on gata3 and il4 expression in Th2 cells, and almost no effects on foxp3 and il10 in Treg cells (Fig. 2C) . These results contrast sharply to the much more broad effects of MS417 on the signature genes of Th17 and Th1 as well as Th2 cells (Fig. 2C) . We confirmed the inhibitory effects of MS402 on additional key Th17 genes il17f, il21, il23r, ahr, irf4, and il9 (Fig.  S2F ). We further observed that MS402 treatment resulted in a marked reduction of Brd4 and Cdk9 occupancy and RNA PolII Ser2 phosphorylation level at the Stat3 binding sites in il17a/f and rorc loci (Fig. S2G) , which is required for transcription elongation (26) . Notably, MS402 seems to have minimal effects on genomic occupancy of Brd2 (Fig. S2G) . Further, MS402 inhibition is independent of IL-10 expression and does not involve IL-27 or IL-35, because it is still able to suppress Th17 and Th1 cell differentiation in il10 −/− mice ( Fig. S2H ) and inhibit activation of il-17a, il17, rorc, ifng, and T-bet in EBI3 −/− mice (Fig. S2I) . We next performed genomic sequencing analysis to better understand how MS402 and JQ1 affect gene transcription in Th17 cell differentiation. Specifically, we carried out chromatin immunoprecipitation sequencing (ChIP-seq) for Brd4 and RNA-seq experiments for mouse Th17 cells with and without MS402 or JQ1 treatment. Overall, MS402 and JQ1 treatments yielded a similar pattern of perturbation in gene transcription in Th17 cell differentiation ( Fig. 3A and Fig. S3 A-D) , albeit certain Th17 signature cytokine genes such as il17a,f and il22 are perturbed slightly even more by MS402 than by JQ1 (Fig. 3B ). Immune and cytokine ontologies seem consistently more enriched in the set of genes down-regulated by MS402 compared with JQ1 (Fig. 3C) , whereas genes up-regulated are clustered in cell development and maturation ( Fig. S3E) . Further, Venn diagram analyses reveal that a majority of MS402-altered genes, with up or down transcriptional expression upon compound treatment, are covered by JQ1, but almost half of JQ1-affected genes are unchanged by MS402 (Fig. 3D) . Notably, violin plot analysis of the RNA-seq data and comparison of the ChIP-seq data show that MS402 is effective similarly to JQ1 in releasing Brd4 genomic occupancy at Th17 signature genes and super enhancers but has fewer effects than JQ1 at housekeeping genes ( Fig. 3E and Fig. S3 F-H) . This apparently selective effect of MS402 over JQ1 is illustrated by representative RNA-seq tracks showing Th17 signature genes Batf and Rorc whose transcription is effectively down-regulated by MS402 or JQ1, whereas a housekeeping gene Oxsm is down-regulated by JQ1 but much less by MS402 (Fig. 3F) . Given that MS402 exhibited cellular inhibitory effects on the order of its affinity for the BD1 of BET proteins, our results collectively suggest that pharmacological inhibition of the BD1 of BET proteins by MS402, likely blocking Brd4 activity required for Th17 signature gene transcriptional activation, is sufficient to render Th17 cell differentiation.
We next examined in vivo effects of MS402 in a T-cell transferinduced colitis model in mice (Fig. 4A) , in which Th17 cells are implicated in disease progression (11) (12) (13) . After reconstitution with naïve CD4 +
CD45RB
hi cells isolated from spleen and lymph nodes of C57BL/6 mice, Rag1 −/− mice began losing weight after 4 wk, whereas the mice that received MS402 intraperitoneally twice a week at 10 mg/kg showed much less weight loss (Fig. 4B) . Histology analysis revealed that 7 wk after reconstitution the colon of the T-cell transfer group mice was markedly shorter and inflamed compared with the control, whereas the colons of MS402-treated mice showed little difference in length or appearance (Fig. 4C) . Notably, unlike the disease mice that exhibited severe inflammation at the end of the study with a disease score of 3, the MS402-treated mice displayed only mild or almost negative inflammation with a disease score of 0-1 (Fig. 4D) . Histological study of colon sections from the disease mice confirmed more severe inflammatory cell infiltrates and significantly higher pathological scores than colons of those treated with MS402 (Fig. 4E) . Finally, the MS402-treated mice showed a significantly lower percentage of IL-17-and IFN-γ-producing CD4 + T cells in colon than the disease mice (Fig. 4F) . Taken together, these results showed that MS402 is effective in vivo, blocking Th17 cell development required for T-cell transfer-induced colitis in mice.
We conducted another in vivo experimental colitis study to explore therapeutic potential of MS402. In this study we started MS402 treatment at week 5 when the Rag1 −/− mice had developed colitis, as judged by marked weight loss, with i.p. injections twice a week at 10 mg/kg for 3 wk (Fig. 4A) . Notably, the mice treated with MS402 exhibited a reversal of weight loss after 1 wk (Fig. 4G) . Consistently, the MS402-treated mice showed an almost minimal degree of inflammation in the colon, as demonstrated by much improved colon length and appearance (Fig. S4A) , a lower disease score of 0-1 (Fig. S4B) , and markedly reduced inflammatory cell infiltrates in colon sections as compared with those of the diseasegroup mice (Fig. 4H) . Further, the MS402-treated mice also had a lower population of IFN-γ-producing CD4 + T cells and exhibited a much more dramatic reduction of IL-17-producing CD4 + T cells in colon than the group of T-cell-transfer disease mice (Fig. 4I) . It is worth noting that the selectivity of MS402 for Th17 over Th1 cells is more profound in this therapeutic treatment model than that in the preventive model (Fig. 4I vs. Fig. 4F ). This differential effect seems to be consistent with the selectivity of MS402 on the maintenance of Th17 over Th1 cells compared with broad effects by pan-BET inhibitor JQ1 after these Th cells are differentiated ex vivo from the mouse primary naïve CD4 + T cells (Fig. S4C) . Finally, the MS402-treated mice had much lower mRNA expression levels of key cytokines and Th17-and Th1-specific transcription factors including il17, il21, il22, il6, rorc, Tbet, and ifng compared with the disease-group mice (Fig. 4J) . Collectively, these results show that MS402 is an effective inhibitor of Th17 cell development and ameliorates adaptive T-cell transfer-induced colitis in mice. Notably, it was recently reported that BET inhibition by JQ1 caused an increased progression of dextran sodium sulfate (DSS)-induced colitis in mice (34) . Although the acute DSS colitis model is useful for study of the innate immune system in the development of intestinal inflammation, T and B cells are not required for the colitis development in this model (35) . Nevertheless, these results highlight multifaceted functions of the BET proteins in adaptive and innate immunity and inflammatory pathology. Further investigation is warranted to determine the mechanistic details of the BET proteins in different functional contexts.
In summary, in this study we show that the BrDs of the BET proteins likely have distinct functions in gene transcription during differentiation of naïve CD4
+ T cells to different T-helper cells, and that the BD1 of Brd4 is central to Th17 cell differentiation and both BD1 and BD2 are important for Th1 and Th2 cell differentiation, whereas neither is essential for Treg cell differentiation. Notably, the BET proteins likely function differently in Th17 cells. Unlike Brd4, Brd2 genomic occupancy is minimally affected by BET inhibition, whereas as reported Brd3 has little expression in Th17 cells (28) . Accordingly, our newly designed BD1-specific inhibitor MS402 is effective and sufficient to render Th17 cell differentiation likely through blocking Brd4 binding to Th17 signature gene loci whose transcriptional activation is required for Th17 cell differentiation. We further showed that selective chemical inhibition of the BD1 of Brd4 by MS402 can effectively prevent and ameliorate T-cell transfer-induced colitis in mice by blocking Th17, and to lesser extent Th1 cell development. Collectively, our study suggests a therapeutic strategy of selective targeting the BD1 of the BET proteins as a promising targeted therapy for inflammatory bowel diseases including colitis that lack a safe and effective treatment.
Materials and Methods
Methods and associated references are available in SI Materials and Methods.
Mice. C57BL/6 wild-type, il10 −/− , and EBI3 −/− mice were obtained from Jackson Laboratory.
Compound. The chemical synthesis and characterization of MS402 is provided in Scheme S1 and Fig. S5 .
Cell Sorting and T-Helper-Cell Differentiation. CD4 + T cells were purified from mouse spleen and lymph nodes using anti-CD4 microbeads (Miltenyi Biotech). Naïve CD4 + T cells were activated with plate-bound anti-CD3 (1.5 μM/mL) and anti-CD28 (1.5 μM/mL) plus cytokines IL-12 (20 ng/mL) and anti-IL4 (10 μM/mL) for Th1 conditions, IL4 (20 ng/mL), anti-IL12 (10 μM/mL), and anti-IFN-γ (10 μM/mL) for Th2 conditions, IL6 (20 ng/mL) and TGF-β (2.5 ng/mL) for Th17 conditions, and TGF-β (2.5 ng/mL) for Treg conditions. The cells were cultured for 2-3 d before harvesting for analysis. All cytokines were purchased from R&D, and neutralizing antibodies were purchased from BD Pharmigen.
Intracellular Staining and Flow Cytometry. Cells were stimulated with phorbol myristate acetate (PMA) and ionomycin for 5 h in the presence of brefeldin A before intracellular staining. Cells were fixed with IC Fixation Buffer (BD Biosciences), incubated with permeabilization buffer, and stained with PE-anti-mouse IL-17, APC-anti-IFN-γ, and PE-Cy 5.5 anti-mouse CD4 antibodies. Flow cytometry was performed on a FACSCalibur and BD LSR Fortessa (BD Biosciences).
Real-Time Quantitative PCR (qPCR).
Total RNA was extracted with RNeasy Mini Kit (Qiagen) and reverse-transcribed using the SuperScript III Reverse Transcriptase (Life Technologies). All qPCR analyses were performed using Brilliant III Ultra Fast SYBR Green QPCR Master Mix (Agilent Technologies). In gene expression analysis all data were normalized with Actin/Gapdh and represented relative to the control sample (fold change). For ChIP-qPCR relative occupancies were calculated as ratio of the amount of immunopreciptated DNA to that of the input sample (percent input). Measurements were performed in duplicate, and error bars denote experimental SDs. Results are representative of more than two independent experiments. Primer sequences are available in Table S2 .
ELISA. All ELISA kits were purchased from eBioscience and experiments were performed according to protocols provided by the manufacturer. Briefly, supernatants of samples were incubated in plates coated with capture antibody. Detection antibody was added after a total of five washes. Avidin-HRP was then added after a total of five washes. Plates were read at 450 nm after addition of substrate solution and stop solution. Concentration of the cytokines in samples was calculated with reference to the absorbance value obtained from the standard curve.
ChIP. Cells were chemically cross-linked with 1% formaldehyde solution for 10 min at room temperature followed by the addition of 2.5 M glycine (to a final concentration of 125 mM) for 5 min. Cells were rinsed twice with cold 1× PBS and then lysed in Szak's RIPA buffer [150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris·HCl, pH 8, 5 mM EDTA, Protease Inhibitor mixture (Roche), and 10 mM PMSF]. Cells were then sonicated using sonicator (QSonica) for 10 pulses of 15 s at a voltage of 70 V, followed by a 1-min rest on ice. Sonicated chromatin was cleared by centrifugation. The resulting chromatin extract was incubated overnight at 4°C with appropriate primary antibody (anti-Brd4 or IHC-00396) and 25 μL of Protein G and 25 μL of Protein A magnetic beads (Dynabeads; Life Technologies). Beads were washed two times with incomplete Szak's RIPA buffer (without PMSF and Protease Inhibitor mixture), four times with Szak's IP Wash Buffer (100 mM Tris·HCl, pH 8.5, 500 mM LiCl, 1% Nonidet P-40, and 1% deoxycholate), then twice again with incomplete RIPA buffer and twice with cold 1× Tris-EDTA. Complexes were eluted from beads in Talianidis Elution Buffer by heating at 65°C for 10 min and then by adding NaCl to a final concentration of 200 mM and reverse cross-linking was performed overnight at 65°C. Input DNA was concurrently treated for cross-link reversal. Samples were then treated with RNaseA and proteinase K for an hour, extracted with phenol/chloroform, and ethanolprecipitated. The pellet was resuspended in water and used for subsequent ChIP-seq library preparation or analyzed by qPCR as described above.
T-Cell-Transfer Colitis Studies and Histopathology. T-cell-transfer colitis was performed as previously described (36, 37) . Briefly, purified CD4 All of the slides were read and scored by an experienced pathologist without previous knowledge of the type of treatment. The degree of inflammation in the epithelium, submucosa, and muscularis propria was scored separately.
Sequencing Library Preparation and Sequencing. ChIPed-DNA was end-repaired with T4 DNA polymerase and polynucleotide kinase. An A-base was added to the end-repaired DNA fragments. Solexa adaptors were ligated to the DNA fragments and 200-to 300-bp size fractions were obtained using E-gel (Life Technologies). Adaptor-modified fragments were enriched by 18 cycles of PCR amplification. The DNA library prep was validated in Bioanalyzer for quantity and size. The input-and ChIPed-DNA libraries were sequenced on the Illumina HiSeq2000 platform with 50-bp read length in a single end mode. RNA-seq libraries were prepared from TRIzol-extracted RNA samples from which rRNA was removed using Ribo-ZeroTM and following the TruSeq Stranded Total RNA Sample Prep kit protocol (Illumina). The input-and ChIP-DNA libraries were sequenced on the Illumina HiSEq. 2000 platform with 50-bp read length in a single end mode. Sequencing of RNA libraries was performed on the Illumina HiSEq. 2000 platform with 100-bp read length in a paired end mode. All ChIPseq and RNA-seq data in this study are deposited in the Gene Expression Omnibus under the accession nos. GSE90788 and GSE95052, respectively.
Bioinformatics Analysis. For ChIP-seq analysis the input and ChIP samples were sequenced by Illumina HiSeq200. After QC filtering by FASTAX (hannonlab.cshl. edu/fastx_toolkit/), only the reads with a quality score Q20 in at least 90% bases were included for analysis. The reads from both input and ChIP samples were filtered and trimmed using Trimmomatic (38) and then aligned to mm9 reference genome using Bowtie. The peaks in the ChIP sample in reference to the input sample were called from read alignments by MACS algorithm (v1.4) and then the distance to the closest transcription start site (TSS) was annotated from genome mapping information of RefSeq transcripts. Genes associated with peaks were annotated (amp.pharm.mssm.edu/Enrichr/). Peaks were chosen with the criteria false discovery rate (FDR) <0.01 and P value <0.005. ChIP-seq from published work was taken from GSE60482 (Th17 p300) (15, 39) . This was treated the same as in-house-generated ChIP-Seq. Finally, the alignment and coverage of ChIPseq data were visualized by Integrative Genomics Viewer (software.broadinstitute.org/software/igv/). Gene annotation and pathway analysis of the identified genes was performed using the Database for Annotation, Visualization and Integrated Discovery (https://david.ncifcrf.gov/). For RNA-Seq analysis the reads were filtered and trimmed using Trimmomatic (38) and aligned to the mm9 mouse reference genome and indexes based on UCSC annotations using TopHat (40) . HTSeq (41) was used to find the read counts across the UCSC reference genome. Differentially expressed genes were identified by the R package DESeq2 (42) using an FDR <0.1 and fold change >1.5. RNA-Seq from Th1 and Th2 cells was taken from GSE40463. These data were analyzed in the same way as inhouse-generated data. Heat maps were derived by sorting all genes with counts ≥5 by log-fold change for each compound treatment. 
